

Donanemab

Cat. No.:	HY-P99859
CAS No.:	1931944-80-7
Target:	Amyloid- β
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (A β) epitope. Donanemab has the potential for early Alzheimer's disease research ^{[1][2]} .
In Vitro	Donanemab is a humanized IgG1 antibody directed at an N-terminal pyroglutamate A β epitope that is present only in established plaques. Donanemab is specific for this epitope and shows no off-target binding to other A β species, neurotransmitters, or their receptors ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Stephen Loucian Lowe, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. *Alzheimers Dement* (N Y). 2021 Feb 14;7(1):e121112.
- [2]. Mark A Mintun, et al. Donanemab in Early Alzheimer's Disease. *N Engl J Med*. 2021 May 6;384(18):1691-1704.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA